Solriamfetol within its marketing authorisation for treating excessive waketime sleepiness caused by narcolepsy
Status Proposed
Process STA 2018
ID number 1602

Provisional Schedule

Committee meeting 07 July 2020
Expected publication 16 September 2020

Project Team

Project lead Gemma Barnacle

Email enquiries

Evidence Review Group / Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton


Companies sponsors Jazz Pharmaceuticals (solriamfetol)
Others Department of Health and Social Care
  NHS England
  NHS Nottingham West CCG
  NHS Tameside & Glossop CCG
  Welsh Government
Patient carer groups British Lung Foundation
  Muslim Council of Britain
  Narcolepsy UK
  Neurological Alliance
  South Asian Health Foundation
  Specialised Healthcare Alliance
  The Brain Charity
  The Sleep Council
Professional groups Association for Respiratory Technology & Physiology
  Association of British Neurologists
  Association of Respiratory Nurse Specialists
  British Association of Neuroscience Nurses
  British Geriatrics Society
  British Neuropathological Society
  British Neuropsychiatry Association
  British Sleep Society
  British Society of Dental Sleep Medicine
  British Thoracic Society
  Institute of Neurology
  National Heart and Lung Institute
  Primary Care and Community Neurology Society
  Primary Care Respiratory Society UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine – Sleep medicine section
  UK Clinical Pharmacy Association


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord-UK (methylphenidate)
  Aurobindo Pharma - Milpharm (modafinil)
  BioProjet (pitolisant hydrochloride)
  Flynn Pharma (dexamphetamine, methylphenidate)
  Generics UK T/A Mylan (methylphenidate)
  Janssen-Cilag (methylphenidate)
  Martindale Pharma (dexamphetamine)
  Novartis Pharmaceuticals UK (methylphenidate)
  Sandoz (methylphenidate,)
  Shire Pharmaceuticals Limited (methylphenidate)
  Teva Pharma (modafinil)
  UCB Pharma (sodium oxybate)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  Neurological Alliance of Scotland
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Wales Neurological Alliance
  Welsh Health Specialised Services Committee
Relevant research groups Brain Research UK
  British Association for Lung Research
  British Neurological Research Trust
  Cochrane Common Mental Disorders Group
  Genomics England
  MRC Clinical Trials Unit
  National Hospital for Neurology and Neurosurgery
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
28 October 2019 Please note that the company have requested additional time in order to facilitate a suitably comprehensive and robust evidence submission. NICE have agreed to this and the new deadline for submissions is expected to be early-January 2020.
08 August 2019 Invitation to participate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance